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C urrently, cardiovascular diseases (CVDs) are the main noncommunicable conditions accounting for 7–10% 
hospitalization and 9.2% of total deaths in Africa.[1] CVDs 
account for at least one million deaths in sub-Saharan Africa[2] 
and compared to 1990 there has been a predominant increase 
in age-standard mortality of all causes of CVD mortality of 
81% (95% confidential interval [CI] =306.2–351.7), ranging 
from 7% (95% CI = 7.5–13.7) rise of ischemic heart diseases 
to a 196% (95% CI = 0.3–0.5) increase in atrial fibrillation.[3] 
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ABSTRACT
Background: Cardiovascular diseases (CVDs) are often accompanied with comoribidities and complications 
leading to taking multiple drugs and thus are more liable to be exposed to drug‑related problems (DRPs). 
DRPs can occur at any stages of medication process from prescription to follow‑up treatment. However, a 
few studies have assessed the specific risk factors for occurrence of at least one potential DRP per patient 
with CVDs in sub‑Saharan African region. Aim: We aim to assess the risk factors for developing potential 
DRPs in patients with CVDs attending Gondar University Referral Hospital (GUH). Methodology: This was a 
cross‑sectional study. A structured systematic data review was designed focusing on patients with CVDs (both 
out and inpatients) with age >18 years of both genders attending GUH from April to June 2015. All DRPs 
were assessed using drugs.com and Medscape. The causes of DRPs were classified using Pharmaceutical 
Care Network Europe version 6.2. Risk factors that could cause DRPs were assessed using binary logistic 
regression showing odds ratio with 95% confidential interval. Statistical significance was set at P < 0.05. 
Results: A total of 227 patients with CVDs were reviewed with a mean age of 52.0 ± 1.7 years. Majority 
were females (143, 63%), outpatients (133, 58.6%), and diagnosed with heart failure (71, 31.3%). Diuretics 
(199, 29.5%) were the most commonly prescribed drugs. A total of 265 DRPs were identified, 63.4% of patients 
have at least one DRP (1.17 ± 1.1). The most common DRPs were found to be an inappropriate selection 
of drug (36.1%) and dose (24.8%). The most identified risk factors causing DRPs were: Need of additional 
drug therapy and lack of therapeutic monitoring. Conclusion: The most identified risk factors for developing 
DRPs were the need of additional drug therapy and lack of therapeutic monitoring. There is a need for clinical 
pharmacist interventions to monitor and prevent the risk of developing DRPs and contribute to improve the 
clinical outcome in patients with CVDs.
KEY WORDS: Cardiovascular diseases, clinical pharmacist, drug related problems, ethiopia, Pharmaceutical 
Care Network Europe, risk factors
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Today, CVD is second only to HIV/AIDs as the leading cause 
of death in adults over 30.[4,5]
In Ethiopia, CVDs have taken over from HIV as the leading 
cause of death. More than half of the deaths in its capital city, 
Addis Ababa are attributed to noncommunicable diseases with 
females more likely to die from CVDs than men.[6] CVD risk 
factors such as overweight and physical inactivity are on the 
rise. This may be attributable to progressive urbanization and 
adopting a western lifestyle in this region.[7-9]
Patients with CVDs, like other chronic diseases, require 
medication. In recent years, there has been a consistent increase 
in the number of medications (polypharmacy) used in patients 
with CVD. Polypharmacy can be defined as concurrent use of 
multiple medication[10] or use of more drugs than clinically 
indicated or two or more drugs of the same class to treat 
same conditions.[11] Four out of five patients with CVD, in a 
Bangladesh study, took an average of 7.3 different drugs a day.[12] 
This rise in a number of drugs prescribed has been associated 
with negative health outcomes some of which include, frequent 
hospitalization, waste of resources, and different drug-related 
problems (DRPs).[13-16]
DRPs is defined as an event or circumstance involving drug 
therapy that actually or potentially interferes with desired 
health outcomes.[17] DRPs can arise at all stages of medication 
process from prescription to follow-up treatment.[18] Findings 
from some studies demonstrated that the frequency of DRPs 
in CVD patients has been ranging from 30.8% to 78%.[19,20] The 
prevalence of DRPs in CVD patients correspondents to 4.9% 
per patients with an incidence rate of 91.7%.[21] Furthermore, 
multiple medications use poses an increasing risk for developing 
at least one DRP in patients with CVD. Early identification 
of these risk factors can improve the patients’ quality of life 
and prevent potential events.[22] A literature review revealed 
no results particularly focusing on DRPs in Ethiopian CVD 
patients. In this regard, we aimed to characterize the occurrence 
of DRPs and to assess the risk factors for developing potential 
DRPs in patients with CVDs attending Gondar University 
Referral Hospital (GUH), Gondar, North-West Ethiopia.
Ethical approval
The study was approved by the Institutional Ethical Committee, 
University of Gondar, School of Pharmacy, Gondar, Ethiopia. 
Written informed consent was obtained from each patient to 
review their medication chart before the data collection.
Methodology
This was a cross-sectional study design conducted from 
April to June 2015 in Cardiology Unit in GUH. Gondar is 
a historical city located in North-Western part of Ethiopia, 
approximately 738 km from the capital city Addis Ababa. GUH 
is 550 bedded teaching referral hospital treating approximately 
201,992 (annually) patients living in and around Gondar.[23] The 
Cardiology Unit constitutes 18 beds and also provide outpatient 
services on every Monday of the week. From April 2015, 
six newly graduated clinical pharmacists were allocated in 
Cardiology Units (in and outpatients) to provide comprehensive 
pharmaceutical care. For research purpose, pharmacists were 
requested to extract and record the drugs used for the patients 
in Cardiology Unit (in and outpatients) in a separate data 
collection form at GUH.
Study population
All patients with CVDs who were either admitted to Cardiology 
Unit or visiting outpatient clinics on Mondays, met the inclusion 
criteria and willing to participate in the study were followed up 
by six clinical pharmacists.
Inclusion and exclusion criteria
Ethiopian	 patients,	≥18	 years,	 both	 genders,	 inpatients	
and outpatients, attending Cardiology Unit, using mainly 
cardiovascular medications were included in the study. CVD 
patients attending emergency ward and re-admitted during the 
study were excluded from the study.
Data collection
A specially designed data collection from was used to collect 
the data for the research purpose and the following data were 
collected: Sociodemographic characteristics, clinical data of 
the patients that includes medical/drug history, laboratory 
values, number of drugs prescribed, patient diagnosis, 
comorbidities, and status of the patients (in/outpatient). 
Factors assumed to increase the risk of acquiring a DRP 
such as polypharmacy (defined as five or more drugs),[24] 
increased	 serum	 creatinine	 levels	 (≥1.5	mg/dl),	 diabetes	
mellitus, cardiac failure, history of allergy, adverse events 
to drugs, and use of narrow therapeutics index drugs that 
could affect to cause DRPs were all recorded to assess the 
outcomes.
All the data were collected by the six clinical pharmacists 
during their daily medication review process and were classified 
according to the Pharmaceutical Care Network Europe (PCNE) 
classification for DRPs version 6.2 (Pharmaceutical Care 
Network Europe [homepage on the Internet]. The PCNE 
Classification for drug-related problems V 6.2. [updated 
January 14, 2010]. Available from: http://www.pcne.org/sig/
drp/documents/PCNE%20classification%20V6-2.pdf. [Last 
accessed March, 2015]). To identify the DRPs resources such as 
Micromedex, Medscape, up-to-date and drugs.com were used 
and these were also used to aid the pharmacists in the provision 
of comprehensive pharmaceutical care in Cardiology Unit.
Assessment and classification of drug‑related problems
DRPs were classified according to PCNE version 6.2 
(Pharmaceutical Care Network Europe [homepage on the 
Internet]. The PCNE Classification for drug-related problems 
V 6.2. [updated January 14, 2010]. Available from: http://www.
pcne.org/sig/drp/documents/PCNE%20classification%20V6-2.
pdf. Accessed March, 2015).[17] The classification used was based 
Abdela, et al.: Drug-related problems in patients with cardiovascular diseases
Journal of Pharmacy and Bioallied Sciences  October-December 2016  Vol 8  Issue 4  291 
on two domains 1. The problem identified (e.g., therapeutic 
effectiveness, adverse reactions, treatment costs, and others), 
and 2. The causes of DRPs (drug selection, drug form, dose 
selection, treatment duration, drug use/administration process, 
logistics, patient behavior, and others). Patient behavior such 
as forgot to use or take drug and stored drugs inappropriately.
Statistical analysis
All the statistical analysis was performed using the SPSS 21.0 
statistical package (IBM Corp., New York, USA). Descriptive 
data were presented in frequencies and percentage with mean 
and standard deviations. Bivariate analysis was performed and 
variables with P < 0.2 were included in the multivariate logistic 
regression analysis. Odds ratio (OR) with 95% confidence interval 
was also computed for each variable for the corresponding P value. 
The value of P < 0.05 was considered as statistically significant.
Results
A total of 312 patients were followed in Cardiology Unit during 
the study. Of which, 64 (20.51%) were younger than 18 years, 
19 (6.08%) patients were transferred to an emergency ward and 
2 (0.64%) with an unclear diagnosis. After application of the 
inclusion and exclusion criteria, 227 (72.75%) adult patients 
were included in the study.
The mean age of the study patients was 52 ± 1.7 (range: 18–85) 
years, and the majority (63.0%) were female patients. Among 
patients who visited Cardiology Unit 133 (58.6%) were 
outpatients and 94 (41.4%) were inpatients. These were 
diagnosed with heart failure (71, 31.3%), valvular heart 
disease (61, 26.9%), hypertension (32, 14.1%), and other heart 
diseases, such as dilated cardiomyopathy and angina (33, 
14.5%) [Table 1]. Ninety-eight (43.1%) patients were with more 
than five comorbidities, (mean value 5.8 ± 0.8). Polypharmacy 
was confirmed in 151 patients (57%) and was evident on 
118 (44.5%) CVD patients with comorbidities. The mean 
number of medications was 4.9 ± 2.1 per patient, while the mean 
hospital stay was 4.9 ± 3.1 days per patient in cardiology ward.
A total of 644 CV drugs were prescribed to the study population, 
with a mean of 3.5 ± 1.5 drugs per patient. The most commonly 
prescribed CV drug class included diuretics (190, 29.5%), 
followed by angiotensin converting enzyme inhibitors 
(80, 12.42%) and beta-blockers (62, 9.63%). The remaining 
classes of drugs are shown in Figure 1.
A total of 265 DRPs were detected in 227 patients with CVDs. 
At least one DRP was identified in 144 patients (63.4%), with 
a mean number 1.17 ± 1.1 DRP per patient. A higher number 
of at least one DRPs were identified in females (93, 35%), and 
inpatients (73, 27.5%), respectively. In all 265 DRPs detected, 
inappropriate drug selection (36.2%), inappropriate dose 
selection (24.9%), and inappropriate drug use process (14%) 
were the most identified DRPs [Table 2]. The distribution of 
DRPs identified by PCNE scale according to the cardiac diseases 
is shown in Table 3.
The bivariate and multivariate analysis of the CVD patients’ 
demographic and clinical characteristics compared with one 
or more DRPs are shown in Table 4. In the logistic regression 
analysis, some of the variables such as outpatients, patients 
with cardiomyopathy and angina, prescribing large number of 
drugs, the presence of polypharmacy and using other noncardiac 
related drugs influenced a greater extent to develop at least one 
DRP was similarly noticed in both bivariate and multivariate 
analysis [Table 4]. For example, a significant higher OR of 
3.33 (P < 0.001) was predicted in inpatients in multivariate 
analysis than 0.30 (P < 0.001) in bivariate analysis. Similar 
results were also noticed with the presence of polypharmacy 
(0.36 in bivariate and 2.74 in multivariate analysis). However, 
a significant association was noticed with increase in number 
0.47
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Ant platelets
Beta blockers
ACEI/ARBS
Diuretics
Percentage of drugs
Figure 1: The most commonly used drug classes (N=227 patients) 
ACEI: Angiotensin converting enzyme inhibitors, ARBS: Angiotensin 
receptor blockers, CCBS: Calcium channel blockers, GI: Gastrointestinal, 
HAART: Highly active antiretroviral therapy
Table 1: Baseline characteristics (n=227 patients)
Frequency (%)
Age
18‑24 14 (6.2)
25‑30 22 (9.7)
31‑36 13 (5.7)
37‑42 22 (9.7)
43‑48 21 (9.2)
49‑54 26 (11.5)
55‑60 34 (15.0)
>60 75 (33.0)
Gender
Male 84 (37.0)
Female 143 (63.0)
Patient’s clinical setting
Outpatient 133 (58.6)
Inpatient 94 (41.4)
Diagnosis
Heart failure 71 (31.3)
Valvular heart disease 61 (26.9)
Ischemic heart disease 20 (8.8)
Arrhythmia 10 (4.4)
Hypertension 32 (14.1)
*Other heart disease 33 (14.5)
Total at each sub row 227 (100.0)
*Other heart disease: Dilated cardiomyopathy and angina
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of drugs for the cardiac patients in both analysis, but the OR 
failed to predict the use of more drugs was reduced from 1.46 
in the bivariate to 0.68 in the multivariate analysis. There was 
no significant difference noticed between gender, age, different 
cardiac diseases, and different cardiovascular drugs (P > 0.05) 
for developing at least one DRP.
Discussion
DRPs in patients with CVDs have been linked to increased 
risk of detrimental patient health outcome. However, it is 
challenging to investigate the risk factors that posesan increased 
risk of developing adverse events. This study was aimed to 
determine the risk factors associated for developing at least one 
DRP in patients with CVDs. We have tested the PCNE criteria 
in representative sample of patients with CVDs attending 
Cardiology Unit (in/outpatient) in GUH, Northwest Ethiopia.
The main findings of the study were the identification of DRPs 
and associated risk factors that are contributing to develop at 
least one DRP per patient with CVDs. We have identified 
certain groups at high risk for developing DRPs, such as older 
patients	(≥60	years),	hospitalized	patients,	polypharmacy,	and	
presence of comorbidities. We found that 63.4% of patients 
with CVDs have at least one DRP, which was much higher 
than that reported by Urbina et al. (29.8%)[19] and Shareef 
et al. (55.3%) studies[25] respectively. However, the number of 
drugs prescribed per patient (3.5 ± 1.5) were associated with a 
higher risk of developing at least one DRP, which was similar to 
study conducted in North-Eastern part of Ethiopia, where the 
mean number of drugs prescribed were 3 ± 1.4 per patient[26] 
and lesser than the studies conducted in Spain (9.25 ± 4.9)[19] 
and Jordan (13.1).[27] These differences in our study may be 
due to several factors such as the cost of drugs, limited access 
to medications and socioeconomic factors.
In this study, nearly 30% of CVD patients taking five or more 
medications (polypharmacy) had at least one DRP. Although, 
other studies not specifically related to CVDs, have also found 
a significant correlation between polypharmacy and the risk of 
adverse drug reactions in especially the elderly population[28] 
and DRPs in hospitalized patients.[29] We have documented 
that for every drug added, there is a 17.7% increase in the risk 
of developing at least on DRPs. This suggests that there was a 
strong relationship between increasing number of drugs and an 
increasing number of DRPs. Hence, polypharmacy stands out as 
a marked risk determinant for heightening the DRPs.
In this study, patients with heart failure and valvular heart disease 
were associated with higher risk of developing at least one DRP, 
but no statistical significance association was noticed. However 
Urbina et al. study conducted on Spanish patients with CVDs 
has shown a significant association for developing at least one 
DRP in patients with heart failure and ischemic heart disease.[19] 
Further, 35.6% of outpatient’s in our study had at least one DRP. 
This percentage is much lower than a study conducted in Geneva, 
where 69% of the outpatients with CVDs had at least one DRP.[22] 
Similarly in another study, 78% of the patients with heart failure 
managed at outpatients clinic had a DRP.[16] This variation was due 
to a lesser number of drugs used in Ethiopian outpatient settings.
In this study, inappropriate drug formulation, dosage selection, 
drug administration process, and patient-specific behavioral 
factors were some of the significant (P < 0.05) causes 
observed for the occurrence of DRPs. In contrast, Tegegne 
et al. study conducted in Felege Hiwot Referral Hospital, 
North-East Ethiopia identified more than 95% (96.1%) were 
due to inappropriate drug indications.[26] Whereas in Jordan, 
drug dosage and drug administration were found to be the 
major type of drugs and therapeutic problems in hospitalized 
patients.[27] These variations may be due to the lack of national 
policies, comprehensive management strategies to manage 
chronic diseases in Ethiopia and depending on self-judgments 
of practitioners while prescribing medications.
Need of additional drug therapy and therapeutic monitoring 
was significantly recognized DRPs in our patients, more than 
Table 2: Distribution of the type of DRPs detected according 
to PCNE scale (n=265 DRPs)
Primary domain Cause Total DRPs (%)
C1: Drug selection Inappropriate drug (including 
contraindicated)
5 (2.0)
No indication for drug 3 (1.1)
Inappropriate combinations 13 (5.0)
Inappropriate duplication of 
therapeutic group
3 (1.1)
Indication for drug therapy not 
noticed
1 (0.4)
More costly drug prescribed 14 (5.2)
Synergistic or preventive drug 
required
10 (3.7)
Need additional drug therapy 47 (17.7)
C2: Dosage form Inappropriate dosage form 8 (3.0)
C3: Dose selection Drug dose too low 10 (3.7)
Drug dose too high 3 (1.1)
Dosage regimen not frequent enough 3 (1.1)
Dosage regimen too frequent 3 (1.1)
No therapeutic drug monitoring 44 (16.5)
Pharmacokinetic problem 
requiring dose adjustment
3 (1.1)
C4: Duration 
of treatment
Duration of treatment too short 2 (0.7)
C5: Drug use 
process
Drug under used/administered 13 (5.0)
Drug over used/administered 2 (0.7)
Drug not taken/administered at all 12 (4.6)
Wrong drug taken 1 (0.4)
Patient unable to use drug or form 
as directed
9 (3.3)
C6: Logistics Prescribed drug not available 8 (3.0)
Prescribing error (information 
wrong or missing)
1 (0.4)
Dispensing error (wrong drug or 
dose)
1 (0.4)
C7: Patient Patient forgets to take drug 9 (3.3)
Patient uses unnecessary drug 4 (1.6)
Patient take food that interact 13 (4.8)
Patient stored drug inappropriate 7 (2.6)
C8: Other Patient unable to buy prescribed 
drug
10 (3.7)
Prescription of drug not included 
in hospital formulary
3 (1.1)
DRPs: Drug‑related problems, PCNE: Pharmaceutical Care Network 
Europe
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half of whom were outpatients. However, similar type of 
concerns was also seen in our hospitalized patients (P < 0.05). 
A cross-sectional observational study conducted in internal 
medicine ward also prioritized need of additional drug therapy 
as a major DRP in GUH.[30] Taking into account that our 
patients were specifically with CVDs and presumably had 
more comorbidities, our corresponding figures of, respectively, 
20.7% and 19.3% were largely in line with the results of that 
study conducted in the same hospital. Compared to previous 
studies the number of DRPs identified in this study were much 
less since drugs for smoking cessation and alcoholism were not 
grouped as DRP unlike in other studies.[27,30] Furthermore, older 
age, having more than one comorbid condition and taking an 
average of four or more drugs per day were an independent 
predictor for developing DRPs. This finding was also previously 
reported in previous studies.[24,31] In 2011, a hospital-based 
study conducted in Southwest Ethiopia identified older age, 
female sex, polypharmacy, and potential drug-drug interactions 
Table 3: Distribution of the main causes of DRPs by type of heart disease
Main cause of DRP Frequency (%) OR (95%CI)* P value
Heart failure 
(n=71)
Valvular heart 
disease (n=61)
Ischemic heart 
disease (n=20)
Arrhythmia 
(n=10 )
Hypertension 
(n=32)
†Others 
(n=33)
Inappropriate combinations 6 (8.5) 3 (5.3) 2 (13.3) 0 (0) 0 (0) 2 (7.1) 1.800 (0.210‑15.407) 0.592
More costly drug prescribed 5 (7) 3 (5.3) 2 (13.3) 1 (12.5) 0 (0) 3 (10.7) 0.641 (0.110‑3.742) 0.484
Synergistic or preventive 
drug
4 (5.6) 2 (3.5) 0 (0) 2 (25) 1 (9) 1 (3.5) 2.400 (0.175‑32.879) 0.512
Need additional drug therapy 13 (18.3) 18 (32.1) 3 (20) 2 (25) 6 (54.5) 5 (17.8) 1.560 (0.267‑9.106) 0.484
Drug dose too low 5 (7.0) 3 (5.3) 0 (0) 0 (0) 1 (9) 1 (3.5) 2.556 (0.282‑23.180) 0.404
No therapeutic drug 
monitoring
15 (21.1) 10 (17.8) 5 (33.3) 2 (25) 3 (27.2) 9 (32.1) 0.852 (0.324‑2.241) 0.745
Drug under used/administered 10 (14.1) 2 (3.5) 0 (0) 0 (0) 0 (0) 1 (3.5) 1.137 (0.099‑13.092) 0.918
Drug not taken/administered 
at all
4 (5.6) 5 (8.9) 0 (0) 0 (0) 0 (0) 3 (10.7) 0.744 (0.156‑3.554) 0.710
Patient take food that 
interact
5 (7.0) 5 (8.9) 2 (13.3) 0 (0) 0 (0) 1 (3.5) 2.818 (0.315‑25.224) 0.354
*Other 4 (5.6) 5 (8.9) 1 (6.7) 1 (12.5) 0 (0) 2 (7.1) 1.938 (0.155‑24.156) 0.607
Total DRPs 71 (100) 56 (100) 15 (100) 8 (100) 11 (100) 28 (100) ‑ ‑
Bivariate logistic regression analysis. *OR: Odds ratio, 95%CI: Confidential interval, P<0.05 set as statistically significant, *Other: Uncategorized, 
†Others: Dilated cardiomyopathy and angina
Table 4: Bivariate and multivariate model of patient’s demographic and clinical characteristics with at least one drug related 
problem versus with no drug‑related problem
Variables Bivariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Sex (female) 0.831 (0.476‑1.450 0.514 1.204 (0.690‑2.100) 0.514
Age (per year) 1.007 (0.991‑1.023) 0.416 1.333 (0.498‑3.569) 0.567
Patients (inpatient) 0.300 (0.165‑0.547) <0.001 3.330 (1.828‑6.067) <0.001
Heart disease
Heart failure 1 (ref) 1 (ref)
Valvular heart disease 1.754 (0.744‑4.138) 0.199 0.570 (0.242‑1.344) 0.240
Ischemic heart disease 1.907 (0.784‑4.638) 0.155 0.524 (0.216‑1.275) 0.155
Arrhythmia 1.719 (0.529‑5.529) 0.368 0.582 (0.179‑1.892) 0.368
Hypertension 1.719 (0.377‑7.849) 0.484 0.582 (0.127‑2.655) 0.127
*Other heart diseases 0.335 (0.121‑0.927) 0.386 2.986 (1.079‑8.259) 0.035
Comorbidities 1.093 (0.773‑1.546) 0.616 0.915 (0.647‑1.294) 0.616
Number of drugs prescribed 1.462 (1.183‑1.907) <0.001 0.684 (0.554‑0.845) <0.001
Presence of polypharmacy 0.364 (0.205‑0.648) <0.001 2.748 (1.544‑4.889) <0.001
Therapeutic class of drugs
Diuretics 0.862 (0.703‑1.057) 0.153 1.090 (0.861‑1.380) 0.474
ACE or ARB’s 0.837 (0.538‑1.303) 0.430 1.298 (0.745‑2.259) 0.357
Beta blockers 1.157 (0.697‑1.918) 0.573 0.924 (0.543‑1.571) 0.770
Calcium channel blockers 0.964 (0.557‑1.669) 0.964 1.089 (0.624‑1.900) 0.763
Cardiac glycosides 1.769 (0.770‑4.066) 0.179 0.591 (0.256‑1.364) 0.218
Anticoagulants 0.878 (0.245‑3.150) 0.842 1.023 (0.276‑3.789) 0.972
Antiplatelets 1.508 (0.721‑3.155) 0.276 0.631 (0.296‑1.347) 0.234
Antibiotics 1.046 (0.974‑1.125) 0.441 0.961 (0.892‑1.034) 0.287
Analgesics and antipyretics 0.789 (0.308‑1.396) 0.218 0.578 (0.102‑3.276) 0.349
Gastrointestinal drugs 1.611 (0.652‑4.232) 0.288 0.637 (0.247‑1.640) 0.349
Anti‑diabetics 1.226 (0.759‑1.979) 0.405 0.830 (0.509‑1.354) 0.455
Other class of drugs 1.222 (1.056‑1.413) 0.007 0.824 (0.713‑0.951) 0.008
CI: Confidence interval, ref‑reference, *Other heart disease includes dilated cardiomyopathy and angina, OR: Odds ratio, significant values are bolded
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were independent risk factors and predicted the occurrence of 
DRPs.[32] In addition, a cohort study in Bahirdar, North-East 
Ethiopia has shown patients with CVDs and associated 
co-morbidities were a predictor for the occurrence of DRPs.[26]
In this study, hospitalized patients with CVD (OR = 3.330; 
95% CI = 1.828–6.067) were about 3 times more likely to 
develop DRP than outpatients. Patients with polypharmacy 
(2.748; 1.544–4.889) were also associated with increased risk 
of DRP. However, these results were also noted in other studies 
conducted on hospitalized patients.[33-37] Nevertheless, a prior 
study identified administration of a certain group of drugs 
during hospitalization (OR = 1.23; 95% CI = 1.15–1.31) as 
independent risk factor for developing DRP in cardiovascular 
patients.[19] Although no significant association between 
the risk of DRP and administration of CV drugs was 
noticed in our study, previous studies identified diuretics 
(OR = 1.7; 95% CI = 1.0–2.6) and psychoactive drugs may 
pose a risk for developing DRPs.[38]
In this study, the mean length of hospital stay for inpatients 
was found to be almost 5 days longer in patients with at least 
one DRP than others. These findings were much less than 
Urbina et al. study (9.58 days).[19] This suggests that increasing 
the number of DRPs can impact the prolonged hospital stay 
and increases the economic burden.[39] A possible solution for 
this findings is the integration of clinical pharmacists in the 
Cardiology Unit which might be helpful to provide exhaustive 
medication review for early detection and prevention of DRPs. 
Topics related to the economic impact of prolonged hospital 
stays need to be further examined.
Study limitations
Certain limitations must be considered when interpreting our 
findings. This study was conducted in one teaching hospital, 
and the results are not necessary representative of other hospitals 
in the country. The study was conducted for a short period 
which may not provide sufficient evidence for the long-term 
outcomes. Furthermore, some of the outpatients included in 
our study were naive patients; therefore, results may not be 
generalized to patients on long-term chronic CVDs. This study 
highlighted only the cardiovascular drugs used by the patients 
during the study period, and other active medications DRPs 
were not included in the study. Although this is a prospective 
cross-sectional study, it was not interventional. We did not assess 
pharmacist interventions and its acceptance by physicians; and 
the impact of DRP on patient outcomes.
Conclusion
The study identified 265 DRPs in 227 patients with CVDs with 
a mean of 1.17 ± 1.1 DRP per patient attending Cardiology 
Unit in GUH. The risk factors for developing DRPs in CVD 
patients were the need of additional drug therapy and lack of 
therapeutic monitoring. Comprehensive medication review by 
clinical pharmacists can aid early identification and prevent the 
DRPs in patients with CVDs in GUH.
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